A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

NCT04088409 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Uveitis

Interventions

DRUG: Baricitinib
DRUG: Adalimumab

Sponsor

Eli Lilly and Company